From NI to tax cuts – what the chancellor of the exchequer could announce at his first fiscal event

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) shareholders have seen the share price descend 10% over the month. But over three years the performance has been really wonderful. In fact, the share price has taken off in that time, up 821%. Arguably, the recent fall is to be expected after such a strong rise. The only way to form a view of whether the current price is justified is to consider the merits of the business itself. Anyone who held for that rewarding ride would probably be keen to talk about it.

Since the long term performance has been good but there's been a recent pullback of 7.4%, let's check if the fundamentals match the share price.

Check out our latest analysis for Aclaris Therapeutics

Given that Aclaris Therapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Aclaris Therapeutics' revenue trended up 13% each year over three years. That's pretty nice growth. Arguably the very strong share price gain of 110% a year is very generous when compared to the revenue growth. A hot stock like this is usually well worth taking a closer look at, as long as you don't let the fear of missing out (FOMO) impact your thinking.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

Aclaris Therapeutics shareholders are down 15% over twelve months, which isn't far from the market return of -16%. So last year was actually even worse than the last five years, which cost shareholders 7% per year. It will probably take a substantial improvement in the fundamental performance for the company to reverse this trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 3 warning signs we've spotted with Aclaris Therapeutics (including 1 which is a bit unpleasant) .

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

On Black Wednesday anniversary, sterling hits 37-year low against dollar and 17-month low against euro

Exposure to blue light from use of tablets and smartphones, may alter hormone levels in young children, scientists say.

Major players in the companion diagnostics market are F Hoffmann-La Roche Ltd, Agilent Technologies Inc, Qiagen NV, Thermo Fisher Scientific Inc, Abbott Laboratories Inc, Myriad Genetics Inc, Almac Group, Illumina Inc, Seimens Healthineers AG, Abnova Corporation, Guardant Health Inc, ARUP Laboratories Inc, Foundation Medicine Inc, Bayer AG, Clinical Lab Products, Leica Biosystems Nussloch GmbH and Life Technologies Tm.New York, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the re

LONDON (Reuters) -Shell said on Friday it was "unaffected" by the German government's decision to place the PCK Schwedt oil refinery under a trusteeship, effectively taking control away from Russian majority owner Rosneft. It is unclear who will step in to replace Rosneft as operator of the 233,000 barrel per day refinery, which Shell has sought to sell out of. "Shell remains unaffected by this order as a 37.5% shareholder in PCK Schwedt and will continue to comply with its contractual obligations in accordance with its own shares," Shell said in an emailed statement.

Knight Frank study predicts Prime Central London market will outperform rest of UK

It came as the euro area’s annual inflation rate came in as expected at 9.1% in August, up from 8.9% in July. This is more than three times the rate in August 2021.

Finland will seek compensation of up to 8 billion euros ($7.97 billion) if Germany nationalises gas importer Uniper, a Finnish cabinet minister said on Friday. Uniper, which is majority owned by Finnish utility Fortum, said on Wednesday the German government might take a controlling stake in the company as it sought further aid on top of a package agreed with Berlin in July. "It is absolutely clear that Finland will not allow Germany to nationalise Uniper without compensation," Minister of European Affairs and Ownership Steering, Tytti Tuppurainen, told the Finnish parliament.

BUDAPEST (Reuters) -Hungary has extended price caps on fuels and basic foodstuff by three months until the end of the year in a bid to shield households from soaring costs, Prime Minister Viktor Orban's chief of staff told a briefing on Saturday. Budapest has sharply criticised the European Union for imposing sanctions on Russia over its invasion of Ukraine, saying they have failed to weaken Moscow meaningfully while causing a surge in food and energy prices. Combined with falls in the forint to record lows, the price rises have sent Hungary's inflation to two-decade highs, forcing the National Bank of Hungary to hike its base rate sharply to 11.75%.

Major players in the facial recognition market are Aware Inc, Ayonix Corporation, Cognitec Systems GmbH, FacePhi, NEC Corporation, Nuance, Idemia, Thales, Fujitsu, Gemalto NV, Onfido, TECH5 SA, NVISO SA (nViso), Neurotechnology, Techno Brain and id3 Technologies (id3).New York, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Facial Recognition Global Market Report 2022" - https://www.reportlinker.com/p06319890/?utm_source=GNW The global facial recognition

Pensioners have been forced to wait as long as six months for their state pension, with many left out because of the system’s “ludicrous complexity”.

Falls against the dollar are prompted partly by concern about Liz Truss’s economic and energy policies

Sitting on the side of a Jakarta road anxiously waiting for his phone to ping, driver Muhammad Ridwan says it is now barely worth hurtling through thick smog every day to ferry passengers.

McLaren was put at risk of collapse by a global shortage of microchips that left the British supercar manufacturer struggling to deliver orders, new accounts show.

Global Advanced Phase Change Materials Market Global Advanced Phase Change Materials Market Dublin, Sept. 16, 2022 (GLOBE NEWSWIRE) -- The "Advanced Phase Change Materials Market By Application, By Type: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.The global advanced phase change materials market was valued at $1.4 billion in 2020, and is projected to reach $4.5 billion by 2030, growing at a CAGR of 12.61% from 2021 to

Major players in the electronic ceramics market are Maruwa Co Ltd, Kyocera Corporation, CeramTec GmbH, Morgan Advanced Materials, Murata Manufacturing Co Ltd, CoorsTek, Almatis GmbH, Noritake, Vinayak Techno Ceramics, PI Ceramic GmbH, Sparkler Ceramics Pvt Ltd, International Syalons Ltd, Nishimura Advanced Ceramics Co Ltd, Techno Cera Industries, Paul Rauschert Steinbach GmbH, McDanel Advanced Ceramic Technologies, and Ceradyne.New York, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announ

Major players in the point-of-care molecular diagnostics market are Abbott Laboratories, F Hoffmann-La Roche Ltd, BioMérieux SA, Danaher Corporation, Quidel Corporation, Qiagen Gmbh, Biocartis NV, Nova Biomedical, Thermo Fisher Scientific, Dickinson and Company, Mesa Biotech Inc, OraSure Technologies Inc, Bio-Rad Laboratories Inc, Sysmex, Siemens Healthineers, Bayer HealthCare Pharmaceuticals LLC, Alere Inc, Lucira Health Inc, Cue Health, OpGen Inc, Binx Health Inc, Molbio Diagnostics Pct Ltd, G

Major players in the subscription & billing management market are Zuora, Aria Systems, Gotransverse, BillingPlatform, Cleverbridge, Recurly, Digital River, Oracle NetSuite, FastSpring, Juston, Apttus, Vindicia, SaaSOptics, Fusebill, Zoho, Chargebee, Chargify, SAP, Salesforce, ActivePlatform, Conga, Logisense, Rebilly, VeryConnect and Pabbly.New York, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Subscription & Billing Management Global Market Report 202

Both volumes and values of customer spending dropped last month, new data show.

WARSAW/BERLIN (Reuters) -Polish refiner PKN Orlen is interested in taking a controlling stake in the PCK Schwedt refinery that Germany has placed under a trusteeship, effectively removing control from Russia's Rosneft, sources in Berlin and Warsaw familiar with the matter told Reuters on Friday.Warsaw said earlier this year that ending Russian ownership of the refinery was a condition for potentially supplying it with sea-borne oil via a terminal in Gdansk and via Polish pipelines to replace Russian crude. State-controlled PKN Orlen declined to comment, saying it announces planned or implemented projects and investments when decisions are made. The refinery, which was majority-owned by Rosneft, has been testing Germany's resolve to eliminate imports of oil from Russia by the end of the year under European sanctions to punish Moscow for its invasion of Ukraine.

The electricity company saw revenues of 3.7 billion euro in the first six months of 2022, a 1.5 billion euro increase on the same period last year.